These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38692437)

  • 21. Delivery Device Patents on GLP-1 Receptor Agonists.
    Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
    JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-Like Peptide-1 Receptor Agonists: Best Choice for Patients With Cirrhosis and Diabetes?
    Li Y; Wang X
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1142-1143. PubMed ID: 37660768
    [No Abstract]   [Full Text] [Related]  

  • 23. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    Lincoff AM; Brown-Frandsen K; Colhoun HM; Deanfield J; Emerson SS; Esbjerg S; Hardt-Lindberg S; Hovingh GK; Kahn SE; Kushner RF; Lingvay I; Oral TK; Michelsen MM; Plutzky J; Tornøe CW; Ryan DH;
    N Engl J Med; 2023 Dec; 389(24):2221-2232. PubMed ID: 37952131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review].
    Demidova TY; Titova VV; Izmaylova MY
    Ter Arkh; 2023 Nov; 95(10):876-880. PubMed ID: 38159021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
    Gogineni P; Melson E; Papamargaritis D; Davies M
    Expert Opin Pharmacother; 2024 May; 25(7):801-818. PubMed ID: 38753454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
    Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
    J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
    McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
    Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perioperative management of patients on glucagon-like peptide-1 receptor agonists.
    Mizubuti GB; Ho AM; Silva LMD; Phelan R
    Curr Opin Anaesthesiol; 2024 Jun; 37(3):323-333. PubMed ID: 38390914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists.
    Ard JD; Lewis KH; Moore JB
    JAMA; 2024 Jul; 332(1):16-18. PubMed ID: 38744427
    [No Abstract]   [Full Text] [Related]  

  • 31. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
    Tobaiqy M; Elkout H
    Int J Clin Pharm; 2024 Apr; 46(2):488-495. PubMed ID: 38265519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.
    Caruso I; Giorgino F
    Endocrine; 2024 Jun; 84(3):822-835. PubMed ID: 38472620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.
    Lee JM; Sharifi M; Oshman L; Griauzde DH; Chua KP
    JAMA; 2024 Jun; 331(23):2041-2043. PubMed ID: 38776113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    Emanuel EJ; Dellgren JL; McCoy MS; Persad G
    N Engl J Med; 2024 May; 390(20):1839-1842. PubMed ID: 38630999
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
    Camilleri M; Carlson P; Dilmaghani S
    Obesity (Silver Spring); 2024 Feb; 32(2):232-233. PubMed ID: 37927173
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.